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Abstract
Purpose. Deep ® bromatoses are large, often rapidly growing but benign soft tissue tumours. Although surgery is the
mainstay of treatment, in unremitting and aggressive cases the use of cytotoxic chemotherapy may produce objective tumour
responses. Fresh tumour samples from four patients with ® bromatosis were investigated as part of a study of drug resistance
in soft tissue tumours.
Methods. Following short-term culture of ® bromatosis cells in vitro, chemosensitivity to 4-hydroperoxy-ifosfamide, the
active form of ifosfamide and doxorubicin was tested. Following 72-h continuous exposure to each drug, surviving cell frac-
tion was assessed using the lactate dehydrogenase assay.
Results. Mean IC50 values for ifosfamide and doxorubicin were 6.2 and 0.35 m mol/l, respectively. In samples of soft tissue
sarcoma (STS) from the same study the mean IC50 values for ifosfamide and doxorubicin were 14.8 and 1.69 m mol. The
difference in mean ifosfamide IC50 values for ® bromatosis and STS samples was statistically signi® cant.
Discussion. We are not aware of any other report suggesting the use of ifosfamide in this condition. These observations
suggest that, for patients with inoperable or progressive lesions of ® bromatosis causing signi® cant morbidity, it may be valu-
able to include ifosfamide in experimental treatment regimens.
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Introduction
The deep ® bromatoses, also known as desmoid
tumours, are large, often rapidly growing but benign
soft tissue tumours. They are rare with a reported
incidence of 0.2± 0.5 per 100 000 population per year,
most commonly affecting young adults, especially
women. Based on their anatomical location, the deep
® bromatoses can be divided into three subtypes, extra-
abdominal, abdominal and intra-abdominal. Extra-
abdominal ® bromatosis arises principally from the
connective tissue of muscle and the overlying fascia
or aponeurosis and chie¯ y affects the muscles of the
shoulder and pelvic girdles and the thigh. Abdominal
® bromatosis arises from the musculo-aponeurotic
structures of the abdominal wall and tends to occur
in women of child bearing age during or after
pregnancy, leading to the hypothesis that hormonal
factors are important in the aetiology of the condi-
tion. Intra-abdominal ® bromatosis arises inside the
abdominal cavity and includes pelvic and mesenteric
® bromatosis and ® bromatosis in Gardner’s
syndrome.
1 Histologically they are all poorly
circumscribed in® ltrating tumours comprising spindle
cells regularly dispersed in collagen, without atypical
or hyperchromatic nuclei but with very occasional
mitotic ® gures.The presence of numerous or atypical
mitotic ® gures should arouse suspicion of a malignant
lesion.
Following the typical presentation with a soft tissue
mass, diagnosis should be con® rmed, preferably by
needle core biopsy, before treatment is undertaken.
Radical surgical excision is the treatment of choice
due to the in® ltrative nature of the tumour.
2± 4
However, because the tumours are non-malignant
with potential for prolonged survival, even in the
presence of bulky disease, it is desirable to avoid
mutilating surgery.
5,6 Local recurrence occurs in
approximately 40% of cases rising to 90% after
marginal excision.
5,7± 10 Radiotherapy has an
established role both as an adjunct to surgery and for
inoperable cases.
11± 14 Tumour regression following
radiotherapy may be prolonged.
Spontaneous regression of growth and a `plateau
phase’ have been observed in cases of ® bromatosis
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This observation contributes to the reluctance of clini-
cians to use cytotoxic treatments routinely in the
management of an essentially benign disease. Many
clinicians feel that the risk of treatment-related side
effects, particularly the long-term risk of induction of
malignant disease makes this form of treatment unac-
ceptable.However, in unremitting and aggressive cases
the use of hormone or cytotoxic chemotherapy can
more easily be justi® ed and there are several published
reports of the successful use of anti-oestrogens,
including toremifene and tamoxifen,
15± 18 pro-
gesterone,
19non-steroidal anti-in¯ ammatory prostag-
landin inhibiting drugs
16 and various cytotoxic
chemotherapy regimens
20± 23 to control cases of
® bromatosis.
Although many different chemotherapy regimens
have been used, there is no clear agreement between
investigators on which regimen is best. In this report,
we present in vitro chemosensitivity data for tumour
cells growing in short-term culture derived from
samples of excised tumour in four cases of ® broma-
tosis treated by surgery. Tumour cells were exposed
to doxorubicin and ifosfamide, the two ® rst line drugs
most commonly used in the treatment of adult soft
tissue sarcoma (STS) and the results are compared
with typical malignant STS samples.
Methods
Patients
Patients presented here were investigated as part of a
research programme within the Institute of Cancer
Research and the Royal Marsden Hospital to study
mechanisms of drug resistance in patients with soft
tissue tumours. This project has been approved by
the local ethics committee. Sterile samples of fresh
tumour were collected from the operative specimens
of patients undergoing primary surgery for soft tissue
tumours. These samples were studied in the labora-
tory and the results were correlated with the clinical
outcome of the patients. The four patients in the
series found to have a pathological diagnosis of
® bromatosis and evaluable for in vitro cytotoxicity are
described.
Processing of tumour material
Samples of fresh sarcoma tissue were collected under
sterile conditions into L15 Leibovitz culture medium
(Gibco Life Technologies, Paisley, Scotland)
containing the antibiotics gentamicin and amphoter-
icin B. Samples were processed within 48 h of collec-
tion as follows: tissue was subjected to mincing using
sterile crossed scalpels, followed by digestion at 37Ê C
using collagenase (Sigma Chemicals, Poole) at a
working concentration of 500± 1000 IU/ml, diluted
in L15 medium. The duration of digestion varied
according to the rigidity and texture of the sample
and was between 30 min and 2 h. Erythrocytes were
removed using a density gradient (Histopaque-1077;
Sigma Chemicals), and further mechanical disaggre-
gation and cell washing was carried out in order to
achieve a suspension with minimal cell clumping and
debris.
Fibromatosis cells were cultured in tissue culture
¯ asks and maintained in an environment of 5% carbon
dioxide at 37Ê C, in Ham’s F12 medium with
Glutamax (Gibco Life Technologies), supplemented
with 20% heat-inactivated foetal calf serum (FCS)
and the antibiotics gentamicin and amphoteracin B.
Cultures were allowed to equilibrate and were
subjected to several changes of medium in order to
remove further debris over a period of at least 48 h.
All cultures grew as attached monolayers. Samples of
the fresh tumour cell suspensions initially seeded into
tissue culture ¯ asks were used to make cytospin
preparations using a Shandon Cytospin 3 (Life
Sciences International UK Ltd., Basingstoke).Giemsa
stained cytospins were used for veri® cation of tumour
cell content which was greater than 80% in all cases.
Chemosensitivity testing
Fresh tumour cells growing as monolayer cultures
were trypsinised (trypsin± EDTA, Gibco Life
Technologies) to produce a single cell suspension in
Ham’s F12 medium containing 10% FCS. Cells were
dispensed into 96-well tissue culture plates in 200-m l
aliquots at a density of 2 3 10
5/ml± 1 3 10
6/ml.
Cultures were allowed to equilibrate for 24 h in an
humidifying gassing incubator. Doxorubicin (Sigma
Chemicals), obtained as the hydrochloride salt, was
made up in sterile distilled water and stored as frozen
aliquots. Ifosfamide (ASTA Medica, Frankfurt,
Germany), obtained as the activated 4-hydroperoxy
form, was dissolved in sterile distilled water
immediately before use. Freshly prepared drug solu-
tions diluted in tissue culture medium containing
10% FCS were dispensed in aliquots to give the
desired ® nal concentration, over a dose range of
0.1± 2 m M for doxorubicin and 0.5± 100 m M for ifos-
famide.The cultures were then incubated at 37Ê C in
a humidifying gassing incubator for 72 h, with the
cells continuously exposed to the drugs.
Trays of drugs-treated cells were assessed for cell
viability using an LDH-release assay kit (Cytotox96,
Promega Corporation, Southampton, UK) which we
have adapted for use in cytotoxicity testing.
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tissue culture medium was aspirated and replaced
with 200 m l of serum-free phenol red-free Dulbecco’s
medium (Gibco Life Technologies). Cells were
ruptured by freezing to ± 70Ê C and then allowing to
thaw at room temperature. 100 m l of cell lysate was
then removed from each well and dispensed into a
duplicate tray. Fifty microlitres of LDH substrate
mixture were added to each well and the colour reac-
tion allowed to take place for 30± 60 min at room
temperature in the dark. Fifty microlitres of `Stop
80 M.W. Verrill et al.solution’ from the kit were added to each well and
colour absorbance at 492 nm (red) was measured
using a plate reading spectrophotometer. Absorb-
ance readings of control untreated cell wells were
compared to drug-treated wells. Data were calculated
as absorbance of test wells relative to control wells
(mean of at least three replicates), with IC50denoting
the concentration of drug required to cause a 50%
loss of cell viability relative to control. These values
were calculated from plots of log10 drug concentra-
tion (x axis) vs fraction of control absorbance (y
axis).
Cytotoxicity testing results for ® bromatosis samples
were compared with IC50 values from 18 evaluable
cases of soft tissue sarcoma collected in the same
study. The remainder of the STS specimens and the
one other ® bromatosis specimen collected failed to
grow or became contaminated making cytotoxicity
testing impossible. None of the patients with STS
had previously received chemotherapy. Several of the
soft tissue sarcoma specimens had IC50 values for
ifosfamide and/or doxorubicin above the limit of
detection of the cytotoxicity assay. By convention,
IC50 values for these cases were set at the maximum
detectable value, typically 50 m mol/l for ifosfamide
and 5 m mol/l for doxorubicin. The IC50 values for
samples of ® bromatosis and soft tissue sarcoma were
compared using the statistical computer software
package SPSS (SPSS Inc., Chicago, IL) by the (non-
parametric) Mann± Whitney U-test which uses vari-
able rank and so is not affected by the distortion of
the STS sample mean which was produced by limiting
maximum IC50 values.
Results
Out of 97 fresh tissue samples collected, the diagnosis
of ® bromatosis was made in four cases. A photograph
of ® bromatosis cell growth in culture is shown in Fig.
1(a) and the corresponding histological section in
Fig. 1(b). The characteristics of the patients are
detailed in Table 1 and the corresponding chemosen-
sitivity testing results are presented in Table 2. The
mean IC50 for doxorubicin in cases of ® bromatosis
was 0.35 m mol/l. The mean IC50 for ifosfamide was
6.2 m mol/l.The corresponding values for STS samples
were 1.69 and 14.8 m mol/l, respectively. Using the
Mann± Whitney U-test there was a signi® cant differ-
ence between the IC50 values in STS and ® broma-
tosis for ifosfamide (p < 0.01) but not for doxorubicin
(p = 0.1). Comparative values for the two drugs are
presented in Fig. 2(a) and (b).
Discussion
Compared to a panel of soft tissue sarcoma cells in
culture, the IC50values for ® bromatosis cells exposed
to ifosfamide and doxorubicin were lower and, for
ifosfamide, this difference was statistically significant.
In STS we have previously shown that a high value
IC50 for the drugs is associated with clinical drug
resistance.
25,26We have been unable to make a similar
comparison for cases of ® bromatosis, no patient has
required systemic therapy. Previous reports have
demonstrated the clinical activity of chemotherapy in
advanced cases of ® bromatosis. A widely used
chemotherapy strategy is the `Philadelphia’ regimen
of low-dose weekly methotrexate (50 mg/week) and
vinblastine (10 mg/week).
20,22 The activity of more
aggressive regimens based on doxorubicin and dacar-
bazine has also been demonstrated
21,23,27 and
additionally, in children, the combination of dacar-
bazine with vincristine and cyclophosphamide (VAC)
has been shown to be effective.
28 We did not have
sufficient clinical material available to test ® broma-
tosis cells against these other cytotoxic drugs.
Table 1. Fibromatosis patient characteristics
Study number 3 41 44 91
Age at diagnosis 24 45 28 31
Sex Female Male Male Female
Clinical setting of sample First relapse (after
45 months)
Primary surgery First relapse (after
23 months)
Primary surgery
Site of tumour Intra-abdominal Upper arm Thigh Abdominal wall
Tumour size (pathological) 11.5 3 8 3 7.5 cm 5 3 3 cm 17 3 7 3 6 cm 13 3 11.5 3 10.5 cm
Adjuvant treatment given? No No Radiotherapy No
Current status Local relapse after 6
months. No further
treatment given.
Remains well with
disease
Alive and disease free Alive and disease free Alive and disease free
Length of follow up 21 months 18 months 18 months 6 months
Table 2. Chemosensitivity testing results for ® bromatosis
patients
Study number
IC50 doxorubicin
(m mol/l)
IC50 ifosfamide
(m mol/l)
3 0.36 5.8
41 0.65 12.9
44 0.27 2.1
91 0.13 4.1
Mean 0.35 6.23
Range 0.13± 0.65 2.1± 12.9
Susceptibility of ® bromatosis cells to ifosfamide 81Our in vitro observations support the inclusion of
doxorubicin in regimens for the treatment of ® broma-
tosis. We have also demonstrated the sensitivity of
® bromatosis cells, at least in tissue culture, to ifosfa-
mide.We are not aware of any other reports suggesting
that ifosfamide is a useful drug in this condition, and
therefore this introduces the possibility of a new
approach to treatment using ifosfamide in ® rst line
drug combinations. For small, well-circumscribed
lesions of ® bromatosis, the treatment of choice should
be surgery. Chemotherapy and radiation therapy
should be avoided because of treatment-related
Fig. 1. (a) Fibromatosis cells growing in tissue culture ¯ ask (unstained). (b) Histological section of ® bromatosis sample from which
cells in Fig. 1(a) were derived (H&E).
82 M.W. Verrill et al.toxicity. However, for patients with inoperable
progressive lesions, causing signi® cant symptoms or
posing a threat to normal organ function, it may be
valuable to include ifosfamide in experimental treat-
ment regimens.
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